Pipeline
Developing Cell and Tissue-Based Therapies for a Range of Aesthetic & Medical Conditions
Bimini is commercializing and investigating autologous and allogenic products & therapies that are ready-to-use at the point-of-care and eliminate the need for matching patients with donors.
Bimini’s product portfolio has already been successfully used in clinical settings in hundreds of thousands of patients worldwide and has trials for androgenic alopecia and osteoarthritis of the knee. Bimini is in the early stages of unlocking the full potential of its product portfolio and adipose derived stem cell technology both in autologous and allogeneic form.
Medical Devices
PRODUCT/BRAND | MARKET | RESEARCH | DEVELOPMENT | CLEARANCE/APPROVAL |
PUREGRAFT 50/250/850 BAGS | US |
|
||
CE MARK |
|
|||
JAPAN |
|
|||
PUREGRAFT MICROFAT | US |
|
||
CE MARK |
|
|||
JAPAN |
|
|||
HEALEON HD PRP | US |
|
||
CE MARK |
|
|||
JAPAN |
|
|||
HEALEON DUET | US |
|
||
CE MARK |
|
|||
JAPAN |
|
|||
DERMAPOSE | US |
|
||
CE MARK |
|
|||
JAPAN |
|
|||
Biologics
PRODUCT/BRAND | MARKET | RESEARCH | DEVELOPMENT | PHASE I/II | PHASE III | APPROVAL |
KERASTEM | US |
|
||||
CE MARK |
|
|||||
JAPAN |
|
|||||
KERASTEM ALLOGENIC | US |
|
||||
CE MARK |
|
|||||
JAPAN |
|
|||||
CONVALESCENT PLASMA | US |
|
||||
CE MARK |
|
|||||
JAPAN |
|